FDA Authorizes ArteraAI Prostate: The First AI-Powered Tool for Prostate Cancer Prognosis

What You Should Know: – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with non-metastatic prostate ... Read More